In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

GSK, Novartis must divest some assets; Perrigo buys OTC brands; Pfizer buys vaccines

Executive Summary

The European Commission, which ensures that EU law is properly applied, approved GlaxoSmithKline PLC's three transactions in oncology, vaccines, and consumer health with Novartis AG (announced in April 2014), but the approval is subject to certain divestments the companies must make following closing of the deals. Buyers of the assets have not yet been disclosed.
Deal Industry
  • Pharmaceuticals
    • OTC, Consumer
    • Vaccines
Deal Status
  • Final
Deal Type
  • Alliance
    • Product Purchase
    • Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register